Skip to main content

Articles

Page 6 of 64

  1. According to current guidelines, more than 70% of patients with invasive submucosal colorectal cancer (T1 CRC) undergo a radical operation with lymph node dissection, even though only ~ 10% have lymph node met...

    Authors: Katsuki Miyazaki, Yuma Wada, Keisuke Okuno, Tatsuro Murano, Yuji Morine, Tetsuya Ikemoto, Yu Saito, Hiroaki Ikematsu, Yusuke Kinugasa, Mitsuo Shimada and Ajay Goel
    Citation: Molecular Cancer 2023 22:2
  2. Small cell lung cancer (SCLC) is an aggressive lung cancer subtype that is associated with high recurrence and poor prognosis. Due to lack of potential drug targets, SCLC patients have few therapeutic options....

    Authors: Parvez Khan, Jawed Akhtar Siddiqui, Prakash G. Kshirsagar, Ramakanth Chirravuri Venkata, Shailendra Kumar Maurya, Tamara Mirzapoiazova, Naveenkumar Perumal, Sanjib Chaudhary, Ranjana Kumari Kanchan, Mahek Fatima, Md Arafat Khan, Asad Ur Rehman, Imayavaramban Lakshmanan, Sidharth Mahapatra, Geoffrey A. Talmon, Prakash Kulkarni…
    Citation: Molecular Cancer 2023 22:1
  3. Lung cancer is the most prevalent form of cancer and has a high mortality rate, making it a global public health concern. The N6-methyladenosine (m6A) modification is a highly dynamic and reversible process that ...

    Authors: Jin Wang, Lirong Tan, Xueting Yu, Xiyuan Cao, Beibei Jia, Rui Chen and Jianxiang Li
    Citation: Molecular Cancer 2022 21:229
  4. Breast cancer metastasis to the bone can be exacerbated by osteoporosis, is associated with poor long-term survival, and has limited therapeutic options. Sclerostin (SOST) is an endogenous inhibitor of bone fo...

    Authors: Lisha Sun, Yixiao Zhang, Guanglei Chen, Yaoting Ji, Qingtian Ma, Xinbo Qiao, Sijin Wu, Lin Zhou, Jiawen Bu, Xudong Zhu, Xiaoying Zhang, Xiaofan Jiang, Chao Liu, Xinnan Li, Yang Liu, Yongliang Yang…
    Citation: Molecular Cancer 2022 21:228
  5. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s12943-017-0586-y.

    Authors: Jia-Xing Zhang, Yi Xu, Ying Gao, Cui Chen, Zhou-San Zheng, Miao Yun, Hui-Wen Weng, Dan Xie and Sheng Ye
    Citation: Molecular Cancer 2022 21:227
  6. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive T-cell malignancy characterized by genotypically-defined and phenotypically divergent cell populations, governed by adaptive landscapes. Clonal expa...

    Authors: Tommaso Colangelo, Patrizio Panelli, Francesco Mazzarelli, Francesco Tamiro, Valentina Melocchi, Elisabetta De Santis, Roberto Cuttano, Orazio Palumbo, Giovanni Rossi, Fabrizio Bianchi and Vincenzo Giambra
    Citation: Molecular Cancer 2022 21:226
  7. Cancer divergence has many facets other than being considered a genetic term. It is a tremendous challenge to understand the metastasis and therapy response in cancer biology; however, it postulates the opport...

    Authors: Palanisamy Nallasamy, Rama Krishna Nimmakayala, Seema Parte, Abhirup C. Are, Surinder K. Batra and Moorthy P. Ponnusamy
    Citation: Molecular Cancer 2022 21:225
  8. Recent studies have identified that circular RNAs (circRNAs) have an important role in cancer via their well-recognized sponge effect on miRNAs, which regulates a large variety of cancer-related genes. However...

    Authors: Yanping Liang, Junjie Cen, Yong Huang, Yong Fang, Yunfei Wang, Guannan Shu, Yihui Pan, Kangbo Huang, Jiaqi Dong, Mi Zhou, Yi Xu, Junhang Luo, Min Liu and Jiaxing Zhang
    Citation: Molecular Cancer 2022 21:224

    The Correction to this article has been published in Molecular Cancer 2023 22:14

  9. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/1476-4598-12-147.

    Authors: Sarita Saraswati, Shakti Kumar and Abdulqader A. Alhaider
    Citation: Molecular Cancer 2022 21:223
  10. Cancer drug resistance represents the main obstacle in cancer treatment. Drug-resistant cancers exhibit complex molecular mechanisms to hit back therapy under pharmacological pressure. As a reversible epigenet...

    Authors: Zaoqu Liu, Haijiao Zou, Qin Dang, Hui Xu, Long Liu, Yuyuan Zhang, Jinxiang Lv, Huanyun Li, Zhaokai Zhou and Xinwei Han
    Citation: Molecular Cancer 2022 21:220
  11. Adoptive cell therapy (ACT) using tumor infiltrating lymphocytes (TIL) is being studied in multiple tumor types. However, little is known about clonal cell expansion in vitro and persistence of the ACT product...

    Authors: Rihao Qu, Yuval Kluger, Junchen Yang, Jun Zhao, David A. Hafler, Diane S. Krause, Alexey Bersenev, Marcus Bosenberg, Michael Hurwitz, Liliana Lucca and Harriet M. Kluger
    Citation: Molecular Cancer 2022 21:219
  12. Esophageal squamous cell carcinoma (ESCC) is a common gastrointestinal malignant tumor, while the molecular mechanisms have not been fully elucidated. Multiple circular RNAs have been reported to involve in th...

    Authors: Lina Gu, Yang Sang, Xixi Nan, Yang Zheng, Fei Liu, Lingjiao Meng, Meixiang Sang and Baoen Shan
    Citation: Molecular Cancer 2022 21:217

    The Correction to this article has been published in Molecular Cancer 2023 22:19

  13. At present, there is no validated marker to identify the subpopulation of patients with advanced gastric cancer (AGC) who might benefit from neoadjuvant chemotherapy (NACT). In view of this clinical challenge,...

    Authors: Ting Guo, Xiao-Huan Tang, Xiang-Yu Gao, Yuan Zhou, Bo Jin, Zi-Qian Deng, Ying Hu, Xiao-Fang Xing, Zi-Yu Li and Jia-Fu Ji
    Citation: Molecular Cancer 2022 21:216
  14. Autoimmune disorders, including Systemic Lupus Erythematosus (SLE), are associated with increased incidence of hematological malignancies. The matricellular protein osteopontin (OPN) has been linked to SLE pat...

    Authors: Celeste Rizzello, Valeria Cancila, Sabina Sangaletti, Laura Botti, Chiara Ratti, Matteo Milani, Matteo Dugo, Francesco Bertoni, Claudio Tripodo, Claudia Chiodoni and Mario P. Colombo
    Citation: Molecular Cancer 2022 21:215
  15. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/1476-4598-13-69.

    Authors: Barbara Nuvoli, Sabrina Germoni, Carlotta Morosetti, Raffaela Santoro, Giancarlo Cortese, Serena Masi, Iole Cordone and Rossella Galati
    Citation: Molecular Cancer 2022 21:214
  16. Inactivation of the Hippo pathway promotes Yap nuclear translocation, enabling execution of a transcriptional program that induces tissue growth. Genetic lesions of Hippo intermediates only identify a minority...

    Authors: Maria E. R. Garcia-Rendueles, Gnana Krishnamoorthy, Mahesh Saqcena, Adrian Acuña-Ruiz, Giovanna Revilla, Elisa de Stanchina, Jeffrey A. Knauf, Rona Lester, Bin Xu, Ronald A. Ghossein and James A. Fagin
    Citation: Molecular Cancer 2022 21:213
  17. Non-small cell lung cancer (NSCLC) patients with primary tumors and liver metastases have substantially reduced survival. Since mesenchymal-epithelial transition factor (MET) plays a significant role in the mo...

    Authors: Yige Sun, Jie Yang, Yingbo Li, Jing Luo, Jiemei Sun, Daoshuang Li, Yuchen Wang, Kai Wang, Lili Yang, Lina Wu and Xilin Sun
    Citation: Molecular Cancer 2022 21:212
  18. The quality and quantity of tumor neoantigens derived from tumor mutations determines the fate of the immune response in cancer. Frameshift mutations elicit better tumor neoantigens, especially when they are n...

    Authors: Daniel Meraviglia-Crivelli, Helena Villanueva, Angelina Zheleva, María Villalba-Esparza, Beatriz Moreno, Ashwathi Puravankara Menon, Alfonso Calvo, Javier Cebollero, Martin Barainka, Igor Ruiz de los Mozos, Carlos Huesa-Berral and Fernando Pastor
    Citation: Molecular Cancer 2022 21:211
  19. Long noncoding RNAs (lncRNAs) have driven research focused on their effects as oncogenes or tumor suppressors involved in carcinogenesis. However, the functions and mechanisms of most lncRNAs in colorectal can...

    Authors: Xue Wang, Han Cheng, Jing Zhao, Jiuming Li, Ying Chen, Kaisa Cui, Lu Tian, Jia Zhang, Chaoqun Li, Shengbai Sun, Yuyang Feng, Surui Yao, Zehua Bian, Shenglin Huang, Bojian Fei and Zhaohui Huang
    Citation: Molecular Cancer 2022 21:210
  20. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s12943-018-0845-6.

    Authors: Fengting Huang, Wenying Chen, Juanfei Peng, Yuanhua Li, Yanyan Zhuang, Zhe Zhu, Chunkui Shao, Wanling Yang, Herui Yao and Shineng Zhang
    Citation: Molecular Cancer 2022 21:209
  21. Tumors are comprised of both cancer cells and surrounding stromal components. As an essential part of the tumor microenvironment, the tumor stroma is highly dynamic, heterogeneous and commonly tumor-type speci...

    Authors: Maosen Xu, Tao Zhang, Ruolan Xia, Yuquan Wei and Xiawei Wei
    Citation: Molecular Cancer 2022 21:208
  22. Exosomes are well-known key mediators of intercellular communication and contribute to various physiological and pathological processes. Their biogenesis involves four key steps, including cargo sorting, MVB f...

    Authors: Qing-Fang Han, Wen-Jia Li, Kai-Shun Hu, Jie Gao, Wen-Long Zhai, Jing-Hua Yang and Shui-Jun Zhang
    Citation: Molecular Cancer 2022 21:207
  23. Natural killer (NK) cells, which are innate lymphocytes endowed with potent cytotoxic activity, have recently attracted attention as potential anticancer therapeutics. While NK cells mediate encouraging respon...

    Authors: Le Tong, Carlos Jiménez-Cortegana, Apple H.M. Tay, Stina Wickström, Lorenzo Galluzzi and Andreas Lundqvist
    Citation: Molecular Cancer 2022 21:206
  24. Brain cancer is regarded among the deadliest forms of cancer worldwide. The distinct tumor microenvironment and inherent characteristics of brain tumor cells virtually render them resistant to the majority of ...

    Authors: Xuchen Qi, Saurabh Kumar Jha, Niraj Kumar Jha, Saikat Dewanjee, Abhijit Dey, Rahul Deka, Pingal Pritam, Kritika Ramgopal, Weiting Liu and Kaijian Hou
    Citation: Molecular Cancer 2022 21:204
  25. Chimeric antigen receptor (CAR) T cell (CAR-T cell) therapy based on gene editing technology represents a significant breakthrough in personalized immunotherapy for human cancer. This strategy uses genetic mod...

    Authors: Chunrun Qu, Hao Zhang, Hui Cao, Lanhua Tang, Haoyang Mo, Fangkun Liu, Liyang Zhang, Zhenjie Yi, Lifu Long, Luzhe Yan, Zeyu Wang, Nan Zhang, Peng Luo, Jian Zhang, Zaoqu Liu, Weijie Ye…
    Citation: Molecular Cancer 2022 21:201
  26. Immune checkpoint blockade has recently proven effective in subsets of patients with esophageal adenocarcinoma (EAC) but little is known regarding the EAC immune microenvironment. We determined the single cell...

    Authors: Wayne Croft, Richard P. T. Evans, Hayden Pearce, Mona Elshafie, Ewen A. Griffiths and Paul Moss
    Citation: Molecular Cancer 2022 21:200
  27. Chimeric fusion transcription factors are oncogenic hallmarks of several devastating cancer entities including pediatric sarcomas, such as Ewing sarcoma (EwS) and alveolar rhabdomyosarcoma (ARMS). Despite thei...

    Authors: Tilman L. B. Hölting, Florencia Cidre-Aranaz, Dana Matzek, Bastian Popper, Severin J. Jacobi, Cornelius M. Funk, Florian H. Geyer, Jing Li, Ignazio Piseddu, Bruno L. Cadilha, Stephan Ledderose, Jennifer Zwilling, Shunya Ohmura, David Anz, Annette Künkele, Frederick Klauschen…
    Citation: Molecular Cancer 2022 21:199
  28. Metastasis of breast cancer have caused the majority of cancer-related death worldwide. The circRNAs are associated with tumorigenesis and metastasis in breast cancer according to recent research. However, the...

    Authors: Peng Liu, Zehao Wang, Xueqi Ou, Peng Wu, Yue Zhang, Song Wu, Xiangsheng Xiao, Yuehua Li, Feng Ye and Hailin Tang
    Citation: Molecular Cancer 2022 21:198
  29. Oncolytic viruses (OVs) represent a new class of multi-modal immunotherapies for cancer, with OV-elicited antitumor immunity being key to their overall therapeutic efficacy. Currently, the clinical effectivene...

    Authors: Zhi Zhu, A. J. Robert McGray, Weijian Jiang, Binfeng Lu, Pawel Kalinski and Zong Sheng Guo
    Citation: Molecular Cancer 2022 21:196
  30. Papillary thyroid carcinoma (PTC) is one of the most common forms of thyroid cancer with a cure rate of over 90% after surgery. However, aggressive forms may still occur, and personalized therapeutic strategie...

    Authors: Emilie Renaud, Kristina Riegel, Rossana Romero, Kushal Suryamohan, Ute Distler, Stefan Tenzer, Arno Schad, Thomas J. Musholt and Krishnaraj Rajalingam
    Citation: Molecular Cancer 2022 21:195
  31. EGFR-TKI targeted therapy is one of the most effective treatments for lung cancer patients harboring EGFR activating mutations. However, inhibition response is easily attenuated by drug resistance, which is ma...

    Authors: Xueli Tian, Rui Wang, Tingxuan Gu, Fayang Ma, Kyle Vaughn Laster, Xiang Li, Kangdong Liu, Mee-Hyun Lee and Zigang Dong
    Citation: Molecular Cancer 2022 21:193
  32. Circular RNAs (circRNAs) act as gene expression regulators and are involved in cancer progression. However, their functions have not been sufficiently investigated in nasopharyngeal carcinoma (NPC).

    Authors: Yongzhen Mo, Yumin Wang, Yian Wang, Xiangying Deng, Qijia Yan, Chunmei Fan, Shuai Zhang, Shanshan Zhang, Zhaojian Gong, Lei Shi, Qianjin Liao, Can Guo, Yong Li, Guiyuan Li, Zhaoyang Zeng, Weihong Jiang…
    Citation: Molecular Cancer 2022 21:192
  33. In vivo gene editing of somatic cells with CRISPR nucleases has facilitated the generation of autochthonous mouse tumors, which are initiated by genetic alterations relevant to the human disease and progress a...

    Authors: Nastasja Merle, Sabrina Elmshäuser, Florian Strassheimer, Michael Wanzel, Alexander M. König, Julianne Funk, Michelle Neumann, Katharina Kochhan, Frederik Helmprobst, Axel Pagenstecher, Andrea Nist, Marco Mernberger, André Schneider, Thomas Braun, Tilman Borggrefe, Rajkumar Savai…
    Citation: Molecular Cancer 2022 21:191
  34. Anaplastic thyroid carcinoma (ATC) is an extremely malignant type of endocrine cancer frequently accompanied by extrathyroidal extension or metastasis through mechanisms that remain elusive. We screened for th...

    Authors: Zongfu Pan, Tong Xu, Lisha Bao, Xiaoping Hu, Tiefeng Jin, Jinming Chen, Jianqiang Chen, Yangyang Qian, Xixuan Lu, Lu li, Guowan Zheng, Yiwen Zhang, Xiaozhou Zou, Feifeng Song, Chuanming Zheng, Liehao Jiang…
    Citation: Molecular Cancer 2022 21:190
  35. Over the past decade, immune checkpoint inhibitor (ICI) therapy has been established as the standard of care for many types of cancer, but the strategies employed have continued to evolve. Recently, much clini...

    Authors: Roger J. Daly, Andrew M. Scott, Oliver Klein and Matthias Ernst
    Citation: Molecular Cancer 2022 21:189
  36. Lung cancer is one of the fatal cancers worldwide, and over 60% of patients are lung adenocarcinoma (LUAD). Our clinical data demonstrated that DNA methylation of the promoter region of miR-126-3p was upregula...

    Authors: Lu Liang, Huiyu Cen, Jionghua Huang, Aiping Qin, Wenyan Xu, Siran Wang, Zhijun Chen, Lin Tan, Qiqi Zhang, Xiyong Yu, Xin Yang and Lingmin Zhang
    Citation: Molecular Cancer 2022 21:186
  37. Chimeric antigen receptor (CAR) T-cell therapy using brexucabtagene autoleucel (BA) induces remission in many patients with mantle cell lymphoma (MCL), and BA is the only CAR T-cell therapy approved by the FDA...

    Authors: Vivian Changying Jiang, Dapeng Hao, Preetesh Jain, Yijing Li, Qingsong Cai, Yixin Yao, Lei Nie, Yang Liu, Jingling Jin, Wei Wang, Heng-Huan Lee, Yuxuan Che, Enyu Dai, Guangchun Han, Ruiping Wang, Kunal Rai…
    Citation: Molecular Cancer 2022 21:185
  38. Up to 80% of cases of prostate cancer present with multifocal independent tumour lesions leading to the concept of a field effect present in the normal prostate predisposing to cancer development. In the prese...

    Authors: Claudia Buhigas, Anne Y. Warren, Wing-Kit Leung, Hayley C. Whitaker, Hayley J. Luxton, Steve Hawkins, Jonathan Kay, Adam Butler, Yaobo Xu, Dan J. Woodcock, Sue Merson, Fiona M. Frame, Atef Sahli, Federico Abascal, Iñigo Martincorena, G. Steven Bova…
    Citation: Molecular Cancer 2022 21:183
  39. Multiple myeloma (MM) is a heterogeneous disease with different patterns of clonal evolution and a complex tumor microenvironment, representing a challenge for clinicians and pathologists to understand and dis...

    Authors: Yuanzheng Liang, Haiyan He, Weida Wang, Henan Wang, Shaowen Mo, Ruiying Fu, Xindi Liu, Qiong Song, Zhongjun Xia and Liang Wang
    Citation: Molecular Cancer 2022 21:182

Annual Journal Metrics

  • 2022 Citation Impact
    37.3 - 2-year Impact Factor
    33.1 - 5-year Impact Factor
    5.740 - SNIP (Source Normalized Impact per Paper)
    8.703 - SJR (SCImago Journal Rank)

    2022 Speed
    7 days submission to first editorial decision for all manuscripts (Median)
    76 days submission to accept (Median)

    2022 Usage 
    3,062,329 downloads
    4,920 Altmetric mentions